ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Files An 8-K Results of Operations and Financial Condition

Item2.02

On February16, 2017, ZIOPHARM Oncology, Inc., or the Company,
issued a press release announcing its financial condition and
results of operations for the three months and year ended
December31, 2016.A copy of the press release is furnished as
Exhibit 99.1 and is incorporated herein by reference.

This information, including the information contained in the
press release furnished as Exhibit 99.1, shall not be deemed
filed for purposes of Section18 of the Securities Exchange Act of
1934, as amended, and is not incorporated by reference into any
of the Companys filings, whether made before or after the date
hereof, regardless of any general incorporation language in any
such filing.

2

About ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)

ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex. The Company’s Ad-RTS-IL-12 + veledimex has been evaluated in two Phase II studies, the first for the treatment of metastatic melanoma, and the second for the treatment of unresectable recurrent or metastatic breast cancer. It has initiated the Phase I study for malignant glioma. The Company has completed the Phase II monotherapy studies in melanoma and breast cancer using Ad-RTS-IL-12 + veledimex. It has initiated a Phase Ib/II study of Ad-RTS-hIL-12 + veledimex following chemotherapy for the treatment of patients with locally metastatic breast cancer. Its initial drug candidate being developed using the synthetic immuno-oncology platform is Ad-RTS-IL-12 + veledimex.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Recent Trading Information

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) closed its last trading session down -0.10 at 6.81 with 1,067,571 shares trading hands.